dapagliflozin

Ligand id: 4594

Name: dapagliflozin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: dapagliflozin

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 99.38
Molecular weight 408.13
XLogP 2.94
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved to treat diabetes mellitus, type 2.
The fixed-dose drug Xigduo XR® contains dapagliflozin (as dapagliflozin propanediol monohydrate PubChem CID 56841155) and metformin hydrochloride.
Results have been published for trial NCT03036124 and these conclude that dapagliflozin reduced worsening heart failure or death from cardiovascular causes irrespective of diabetes status, in patients with heart failure and a reduced ejection fraction [3]. Clinical trial NCT03619213 is evaluating whether this efficacy is retained in patients with heart failure and preserved ejection fraction.
Mechanism Of Action and Pharmacodynamic Effects
Dapagliflozin inhibits sodium-glucose transport protein subtype 2 (SGLT2), which accounts for >90% of glucose reabsorption from the kidneys. Inhibition of this transporter leads to excretion of blood glucose into urine. Dapagliflozin is >1000 times more inhibitory at SGLT2 than SGLT1, meaning that its effects on intestinal glucose absorption are negligible. Although this drug could be equally effective in treating type 1 diabetes, its approval restricts use to type 2 disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03036124 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure Phase 3 Interventional AstraZeneca
NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Phase 3 Interventional AstraZeneca
External links